NewAmsterdam Pharma Company N.V.

NasdaqGM:NAMS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

💉 Vaccines

Location

Netherlands

Market Cap

USD 2.02 B

Share Price

USD 17.96

Avg Daily Volume

921,979

Change (1 day)

-1.32%

Change (1 year)

4.24%

Change (YTD)

-30.12%

NewAmsterdam Pharma Company N.V. Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2025: USD 84.04 M

NewAmsterdam Pharma Company N.V. Selling, General, and Administrative Expenses (SG&A) is USD 84.04 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 88.52% change year over year. Selling, general, and administrative (SG&A) expenses are the expenses related to the sales and marketing efforts, as well as general and administrative functions of a company.

NewAmsterdam Pharma Company N.V. Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 44.58 M, a 101.07% change year over year.
NewAmsterdam Pharma Company N.V. Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 22.17 M, a 140.37% change year over year.
NewAmsterdam Pharma Company N.V. Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 9.22 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Selling, General, and Administrative Expenses (SG&A)	Research and Development (R&D) Expenses	Revenue	Revenue

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	68
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals 💉 Vaccines

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.